OptumRx Spotlights Two Drugs That Treat Rare Liver Diseases

In OptumRx’s latest Drug Pipeline Report, the UnitedHealth Group-owned PBM highlights a pair of drugs that offer long-sought treatments for two forms of liver disease. Because those diseases are so uncommon, the price of those drugs is likely to be quite high.

The drugs in question are Bylvay (odevixibat), which the FDA approved on July 20, and maralixibat, which the agency is expected to approve in late September. Bylvay, which is manufactured by Albireo Pharma, Inc., is the first drug approved for treating pruritus — or persistent itchiness — in all subtypes of progressive familial intrahepatic cholestasis (PFIC), a group of three related genetic disorders. Mirum Pharmaceuticals, Inc.’s maralixibat, if approved, would be the first treatment for patients ages 1 year and older with Alagille Syndrome (ALGS), a rare genetic disorder in which bile ducts are abnormally narrow, malformed and reduced in number.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today